SynthesisMicrobiology spectrum2022
Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Synthesis in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 6 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review.BMJ global health · 2024Pooled it
- Colistin monotherapy or combination for the treatment of bloodstream infection caused by Klebsiella pneumoniae: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Pooled it
- Pooled it
- Pooled it
- Ceftazidime-Avibactam Versus Colistin-Based Regimens for Carbapenem-Resistant Enterobacterales Bloodstream Infections: A Six-Year Retrospective Cohort and 30-Day Mortality Analysis.Microorganisms · 2026Article
- Article
- Assessing Clinical Effectiveness of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam in Bacteremia: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Addressing therapeutic options for KPC-3-producing ST307-Antimicrobial agents and chemotherapy · 2026Article
- Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers.Antimicrobial agents and chemotherapy · 2026Article
- Genomic characterization of an extensively drug-resistant Klebsiella pneumoniae co-harboring mcr-3.11, blaNDM-5 and blaCTX-M-27 isolated from pelvic effusion in a colon cancer patient.BMC microbiology · 2026Article
- The pharmacokinetics/pharmacodynamics index of high-dose tigecycline in patients with carbapenem-resistant Enterobacterales bloodstream infection: a prospective study.BMC infectious diseases · 2026Article
- Early procalcitonin kinetics as an independent predictor of mortality in multi-drug resistant Klebsiella spp. bloodstream infections: a retrospective cohort study.BMC infectious diseases · 2026Observational
- Carbapenem-resistant Enterobacterales bacteraemia at a tertiary hospital: A five-year review.Southern African journal of infectious diseases · 2026Article
- Effectiveness and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: a real-world cohort study.Journal of pharmaceutical policy and practice · 2026Article
- Serum proteomic profiling of sepsis patients reveals a protein-based diagnostic model, with metabolomic insights into carbapenem-resistantFrontiers in immunology · 2026Article
- Model-Informed Ceftazidime-Avibactam Dosing Stratified by Renal Function and Renal Replacement Therapy Status in Critically Ill Patients: A Prospective Population Pharmacokinetic and Monte Carlo Simulation Study.Drug design, development and therapy · 2026Article
- Predictors of 30-day mortality in critically ill patients with bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: a five-year retrospective study.BMC infectious diseases · 2025Article
- An Algorithm for Rapid and Low-Cost Detection of Carbapenemases Directly from Positive Blood Cultures Using an Immunochromatographic Test.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several clinicians use ceftazidime-avibactam (CAZ-AVI) to treat bloodstream infections (BSIs) due to carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.